Parexel International Corp. (PRXL)

[surf1944]

6:02AM PAREXEL announces that it has completed a large and complex pharmacogenetics-based early phase study (PRXL) 23.88 : Co announces that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6, an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.